Project Number 2R44AG056231-03A1 Agency/Funding Organization NIA Funding Year 2022 View Full Project Details for Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 4. Non-clinical Drug Development (small molecules and biologics) a. Amyloid beta Researcher and Organization Principal Investigator GREGOR, PAUL Principal Investigator First Name PAUL Principal Investigator Last Name GREGOR Awardee Organization GISMO THERAPEUTICS, INC. Awardee State New York, N.Y. Contact PI Country United States Project Detail Funding Opportunity Announcement PAS-19-316: Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) FY Overall Cost $983,932 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official MARTIN, ZANE
